drugset
drugset / Trial / NCT02617784

A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)

NCT02617784 ↗

Phase 1 Completed 24 enrolled Hoffmann-La Roche
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to assess the pharmacokinetics (PK) and safety of oseltamivir and its metabolite oseltamivir carboxylate in participants undergoing routine HD and CAPD for end-stage renal disease (ESRD). Participants will receive 6.5 and 6 weeks of the marketed oral oseltamivir suspension dosed according to the HD or CAPD schedule, respectively.

Timeline

Start
2001-10
Primary completion
2002-06
Completion
2002-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Oseltamivir Small molecule 30 mg Oral

Indications

end stage renal failure